The expression profile and clinic significance of the SIX family in non-small cell lung cancer by Qian Liu et al.
RESEARCH Open Access
The expression profile and clinic
significance of the SIX family in non-small
cell lung cancer
Qian Liu1†, Anping Li2†, Yijun Tian1, Yu Liu3, Tengfei Li2, Cuntai Zhang3, Jennifer D. Wu4, Xinwei Han2*
and Kongming Wu1*
Abstract
Background: The SIX family homeobox genes have been demonstrated to be involved in the tumor initiation and
progression, but their clinicopathological features and prognostic values in non-small cell lung cancer (NSCLC) have
not been well defined. We analyzed relevant datasets and performed a systemic review and a meta-analysis to
assess the profile of SIX family members in NSCLC and evaluate their importance as biomarkers for diagnosis and
prediction of NSCLC.
Methods: This meta-analysis included 17 studies with 2358 patients. Hazard ratio (HR) and 95 % confidence interval
(CI) were calculated to represent the prognosis of NSCLC with expression of the SIX family genes. Heterogeneity of
the ORs and HRs was assessed and quantified using the Cochrane Q and I2 test. Begg’s rank correlation method
and Egger’s weighted regression method were used to screen for potential publication bias. Bar graphs of
representative datasets were plotted to show the correlation between the SIX expression and clinicopathological
features of NSCLC. Kaplan-Meier survival curves were used to validate our prognostic analysis by pooled HR.
Results: The systematic meta-analysis unveiled that the higher expressions of SIX1-5 were associated with the
greater possibility of the tumorigenesis. SIX4 and SIX6 were linked to the lymph node metastasis (LNM). SIX2, SIX3,
and SIX4 were correlated with higher TNM stages. Furthermore, the elevated expressions of SIX2, SIX4, and SIX6
predicted poor overall survival (OS) in NSCLC (SIX2: HR = 1.14, 95 % CI, 1.00–1.31; SIX4: HR = 1.39, 95 % CI, 1.16–1.66;
SIX6: HR = 1.18, 95 % CI, 1.00–1.38) and poor relapse-free survival (RFS) in lung adenocarcinoma (ADC) (SIX2: HR = 1.
42, 95 % CI, 1.14–1.77; SIX4: HR = 1.52, 95 % CI, 1.09–2.11; SIX6: HR = 1.25, 95 % CI, 1.01–1.56).
Conclusions: Our report demonstrated that the SIX family members play distinct roles in the tumorigenesis of
NSCLC and can be potential biomarkers in predicting prognosis of NSCLC patients.
Keywords: SIX family genes, Lung cancer, Tumor marker, Prognosis, Meta-analysis
Backgrounds
The members of Retinal Determination Gene Network
(RDGN), mainly including DACH, SIX, and EYA, eluci-
dated as a cascaded signal pathway regulating precursor
cell proliferation, differentiation, and survival during
mammalian organogenesis in a cell context-dependent
manner [1–4]. Specifically, decreased EYA1 and SIX1
expression during the late pseudoglandular stage involv-
ing epithelial branching and distal airway maturation led
to the pulmonary hypoplasia (PH) [5]. Transgenic mouse
model demonstrated that deletion of either Six1 or Eya1
genes leads to a defect of mesenchymal cell development
and remodeling of the distal lung septae and arteries [6].
It has been proved that EYA1 and SIX1 played pivotal
roles during lung morphogenesis [7]. Molecular mech-
anism study indicated that in RDGN signaling, SIX func-
tioned as a DNA-binding transcriptional factor, while
EYA and DACH served as co-activator and co-repressor
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of SIX family, respectively, to control gene activation or
repression [4]. However, it was proposed that EYA did
not interact with SIX3 as a co-activator [8].
The SIX family consists of six members divided into
three subfamilies, namely SIX1/SIX2 (So), SIX3/SIX6
(Optix), and SIX4/SIX5 (Dsix4) [9, 10]. The SIX family
members are characterized by two evolutionarily con-
served domains. The SIX domain (SD) is involved in
protein–protein interactions, while homeobox nucleic
acid recognition domain (HD) is related to DNA binding
[11, 12]. SIX family binds to DNA at a core consensus
sequence of TAAT, whereas SIX3 binds to an additional
TGATAC sequence [13]. It has been reported that SIX
family modulates a series of key genes, namely cyclin
A1, cyclin D1, and c-myc. Sufficient evidences have re-
vealed that aberrant expressions of the SIX genes gave
rise to tumorigenesis, tumor progression, and metastasis
by promoting proliferation, angiogenesis, migration, and
apoptosis [14].
The SIX family was reported to be related with non-
small cell lung cancer (NSCLC) recently. Study from Xia
Y et al. indicated that SIX1 promoted the invasion and
proliferation of NSCLC [15]. And Mimae T et al. showed
that upregulation of SIX1 in both messenger RNA
(mRNA) and protein expressions led to lung adenocarcin-
oma (ADC) invasion by inducing epithelial-mesenchymal
transition (EMT) [16]. Moreover, Zhao Y et al. proposed
that SIX6 combined with other co-factors were considered
as promoters to the development of lung squamous cell
carcinoma (SQC) [17]. However, another critical mem-
ber of SIX family, SIX3, was reported to act as a repres-
sor in ADC cell proliferation and migration. More
importantly, SIX3 could remarkably improve overall
survival (OS) and progression-free survival (PFS) in
early stage ADC patients [18]. To comprehensively ex-
plore the effect of different SIX family members in
NSCLC, we analyzed relevant datasets and performed a
systemic review and a meta-analysis to assess the profile
of SIX family members in NSCLC and evaluate their im-




The relevant literatures were obtained from following
databases PubMed, Embase, and Cochrane library pub-
lished up to October 1, 2015 using the search terms
NSCLC (non-small-cell lung cancer, non-small cell lung
cancer), SIX1 (SIX1 protein, human), SIX2 (SIX2 pro-
tein, human), SIX3 (Sine oculis homeobox homolog 3
protein), SIX4 (SIX4 protein, human), SIX5 (SIX5 pro-
tein,human), and SIX6 (SIX6 protein, human). The refer-
ence list including retrieved articles was reviewed to
discover possible associated publications.
Inclusion criteria
Randomized controlled studies (RCTs) or case-control
or cohort studies were selected in this meta-analysis to
evaluate the correlation between the SIX family expres-
sion and NSCLC clinicopathological features and prog-
nosis. The following criteria were strictly observed: (a)
patients recruited into the study were pathologically di-
agnosed as NSCLC; (b) the expressions of the SIX family
genes were extracted from normalized microarray within
primary NSCLC tumor, and median expression was used
as cut-off value. Detailed information for genechips and
platforms was in Table 1; (c) hazard ratio (HR) and 95 %
CI were available or statistically extracted from relevant
literatures [19]. As for reports with the same population,
the most recent or complete report was chosen.
Data extraction
All data were presented in Table 1 with the following in-
formation: first author’s last name, publication year, dur-
ation month, histological type, tumor stage, number of
cases and controls, and detection methods and platforms
for the SIX family. The levels of gene expressions and
NSCLC survival data were obtained from Oncomine and
ArrayExpress. OS and relapse-free survival (RFS) were
calculated by Cox proportional HRs and 95 % CIs.
The Newcastle-Ottawa Quality Assessment Scale (NOS)
was applied to evaluate the quality of these observational
studies. Data from included studies were extracted and
summarized independently by two reviewers, and dis-
agreements were settled by discussion.
Statistical analysis
Meta-Analysis of Observational Studies served as guide-
lines applied for statistical analysis [20]. HRs and 95 % CIs
were calculated to represent the prognosis of NSCLC with
expression of the SIX family genes. Clinicopathological
parameters included histological type, lymph node metas-
tasis (LNM), and TNM stage. Heterogeneity of the ORs
and HRs was assessed and quantified using Cochrane Q
and I2 test. Random-effect model was employed if there
was heterogeneity between studies (p < 0.05 or I2 > 50 %).
Otherwise, fixed-effect model was applied. Begg’s rank
correlation method and Egger’s weighted regression
method were used to screen for potential publication bias.
All p values were two tailed, and all analyses were accom-
plished using STATA software package (version 13.0)
(Stata Corp LP, College Station, TX, USA). We selected
the representative datasets, GSE19188, GSE19804, and
GSE32863 to analyze the significance of SIX expression in
clinicopathological features of NSCLC. The bar graphs
were printed using GraphPad Prism 5.0 software. Un-
paired t test was used to determine differences between
groups.
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Kaplan-Meier plotter
Kaplan-Meier survival curves with hazard ratio and log-
rank p value were calculated and plotted with the ana-
lysis tool which can be accessed online at http://
kmplot.com/analysis/ [21]. The background database,
downloaded from GEO (Affymetrix microarrays only),
EGA, and TCGA, offers gene expression data, relapse-
free, and overall survival information. The software is
capable to assess the effect of 54,675 genes on survival
using 10,188 cancer samples, among which includes
2437 cases of lung cancer. We analyzed the survival out-
comes of NSCLC in different expression levels of SIX2,
SIX4, and SIX6. The Kaplan-Meier survival curves were




The flow diagram reflecting the selection process for in-
clusive studies is illustrated in Fig. 1. Three hundred
thirty-eight studies were screened out depending on
mentioned search strategy. According to requirement
for sample size (n ≥ 50), 237 studies were excluded. After
selecting by assessing article titles, abstracts, and full-
texts, 17 studies with 2358 cases were applied to this
analysis. These studies primarily focused on the causality
between the SIX family expression and the NSCLC pro-
gression and prognosis. The clinicopathological parame-
ters such as histological type, LNM, and TNM stage
Table 1 Characteristics of studies included for meta-analysis. Cut-off value: median expression
First author Year Duration (months) Histology Stage Patient number Quality score Detection Platform
Okayama H [41] 2011 120 ADC I–II 226 9 Microarray Affymetrix Hgu133plus2.0
Hou J [42] 2010 130 NSCLC NR 91 9 Microarray AffymetrixHgu133plus2.0
Tang H [43] 2013 120 NSCLC I–III 176 9 Microarray IlluminaHumanWG-6v3.0
Zhu CQ [44] 2010 108 NSCLC IB–II 133 9 Microarray AffymetrixHgu133a
Raponi M [45] 2006 144 SQC I–III 129 8 Microarray AffymetrixHgu133plus2.0
Bild AH [46] 2006 88 NSCLC NR 111 8 Microarray AffymetrixHgu133plus2.0
Rousseaux S [47] 2013 256 NSCLC I–IV 293 9 Microarray AffymetrixHgu133plus2.0
Tomida S [48] 2009 109.8 ADC I–III 117 9 Microarray AgilentWholeHumanGenomeMicroarray
4x44K G4112F
Botling J [49] 2013 120 NSCLC I–IV 196 8 Microarray AffymetrixHgu133plus2.0
Shedden K [50] 2008 204 ADC I–IV 333 9 Microarray AffymetrixHgu133a
Beer DG [51] 2002 110.6 ADC I–III 86 8 Microarray AffymetrixHumanFullLength HuGeneFL
Landi MT [52] 2008 NR ADC I–IV 74 9 Microarray AffymetrixHgu133a
Lu T [53] 2010 NR ADC I–IV 60 8 Microarray AffymetrixHgu133plus2.0
Lee ES [54] 2008 120 NSCLC I–III 138 8 Microarray AffymetrixHgu133plus2.0
Kuner R [55] 2009 NR NSCLC NR 58 8 Microarray AffymetrixHgu133plus2.0
Selamat SA [56] 2012 NR ADC I–III 58 8 Microarray IlluminaHumanWG-6v3.0 expression
Meyerson M [57] 2015 NR SQC I–IV 135 8 Microarray AffymetrixHgu133a
NR not reporting, ADC lung adenocarcinoma, SQC lung squamous cell carcinoma
Fig. 1 Flow diagram of literature retrieval process
Liu et al. Journal of Hematology & Oncology  (2016) 9:119 Page 3 of 13
were available in every study. The information of relevant
literatures was listed in the Table 1. TNM stages I and II
were defined as low stage, III and IV as high stage.
The expressions of SIX family genes elevated in NSCLC
tissues
The SIX family genes, especially SIX1, SIX2, SIX3, SIX4,
and SIX5, manifested significantly higher expression
level in NSCLC tissues than normal lung tissues (SIX1:
pooled OR = 15.70, 95 % CI, 10.19–24.19, p = 0.953, and
I2 = 0.0 %; SIX2: pooled OR = 4.69, 95 % CI, 3.34–6.59,
p = 0.000, and I2 = 78.9 %; SIX3: pooled OR = 1.96, 95 %
CI, 1.43–2.68, p = 0.540, and I2 = 0.0 %; SIX4: pooled
OR = 20.42, 95 % CI, 12.12–34.41, p = 0.449, and I2 =
0.0 %; SIX5: pooled OR = 2.34, 95 % CI, 1.70–3.22, p =





Fig. 2 Forest plot of odds ratio (OR). CI confidence interval. Relative mRNA level of SIX1 (a), SIX2 (b), SIX3 (c), SIX4 (d), SIX5 (e), and SIX6 (f) in
NSCLC compared with normal lung tissues. Bar graph representation of relative SIX family mRNA level of NSCLC compared with normal lung
tissues in GSE19188 (g) and GSE19804 (h). *p < 0.05, **p < 0.0001
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showed a considerable trend toward significance
(pooled OR = 1.30, 95 % CI, 0.76–2.22, p = 0.038, and
I2 = 57.4 %; Fig. 2f ). Subgroup analysis of ADC was
also proven to have the similar trend (SIX1: pooled
OR = 11.85, 95 % CI, 7.28–19.28, p = 0.218, and I2 =
30.6 %; SIX2: pooled OR = 3.21, 95 % CI, 2.19–4.70,
p = 0.006, and I2 = 72.2 %; SIX3: pooled OR = 1.82,
95 % CI, 1.26–2.62, p = 0.488, and I2 = 0.0 %; SIX4:
pooled OR = 18.89, 95 % CI, 9.69–36.82, p = 0.269,
and I2 = 23.7 %; SIX5: pooled OR = 1.89, 95 % CI,
1.31–2.73, p = 0.045, and I2 = 59.0 %; Fig. 3a–e). SIX6
indicated uncertain significance (pooled OR = 1.05,
95 % CI, 0.58–1.87, p = 0.094, and I2 = 49.6 %; Fig. 3f ).
Expression of SIX family between normal and NSCLC
tissues in the representative dataset GSE19188 showed





Fig. 3 Forest plot of odds ratio (OR). CI confidence interval. Relative mRNA level of SIX1 (a), SIX2 (b), SIX3 (c), SIX4 (d), SIX5 (e), and SIX6 (f) in ADC
compared with normal lung tissues. Bar graph representation of relative SIX family mRNA level of ADC compared with normal lung tissues in
GSE19188 (g) and GSE32863 (h). *p < 0.05, **p < 0.0001
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SIX3: p = 0.004; SIX4: p < 0.0001; SIX5: p = 0.0027; SIX6:
p = 0.0025; Fig. 2g), while the similar tendency was shown
in another representative dataset GSE19804 except SIX6
(SIX1: p < 0.0001; SIX2: p < 0.0001; SIX3: p = 0.0146; SIX4:
p < 0.0001; SIX5: p = 0.0098; SIX6: p = 0.0615; Fig. 2h).
In ADC patients, the expression levels of SIX1-5
were markedly higher than normal in GSE19188
(SIX1: p < 0.0001; SIX2: p < 0.0001; SIX3: p = 0.0129;
SIX4: p < 0.0001; SIX5: p = 0.0193; SIX6: p = 0.077;
Fig. 3g). In GSE32863, only SIX1, SIX2, and SIX4 indi-
cated significant differences between ADC and normal tis-
sues (SIX1: p < 0.0001; SIX2: p = 0.0002; SIX3: p = 0.1021;
SIX4: p < 0.0001; SIX5: p = 0.6497; SIX6: p = 0.5539;
Fig. 3h).
The SIX family gene expressions correlated with TNM
stage of NSCLC
Three SIX genes among the SIX family, namely SIX2,
SIX3, and SIX4, were remarkably correlated with the
TNM stage of NSCLC. The increased expressions of
these genes were associated with advanced tumor stage
(SIX2: pooled OR = 1.30, 95 % CI, 1.00–1.68, p = 0.467,
and I2 = 0.0 %; SIX3: pooled OR = 1.56, 95 % CI, 1.20–
2.04, p = 0.664, and I2 = 0.0 %; SIX4: pooled OR = 1.95,
95 % CI, 1.36–2.79, p = 0.159, and I2 = 39.3 %; Fig. 4a, c,
e). Moreover, the same analysis was also conducted on
ADC. The relationship between SIX2 expression and
TNM stage of ADC was on the verge of statistically sig-
nificant (pooled OR = 1.39, 95 % CI, 0.95–2.02, p = 0.359,
and I2 = 8.3 %; Fig. 4b). However, SIX3 and SIX4 gave
specific tendency in our study (SIX3: pooled OR = 1.81,
95 % CI, 1.22–2.67, p = 0.513, and I2 = 0.0 %; SIX4:
pooled OR = 1.80, 95 % CI, 1.18–2.77, p = 0.336, and
I2 = 11.3 %; Fig. 4d, f ). Subgroup analysis of lung
squamous cell carcinoma (SQC) showed no significance
in SIX2 and SIX3 (see Additional file 1). Among included
databases in our study, GSE68793 (Meyerson M. 2015)




Fig. 4 Forest plot of odds ratio (OR). CI confidence interval. Relative mRNA expression of SIX2 (a), SIX3 (c), and SIX4 (e) between III–IV and I–II
patients in NSCLC. Relative mRNA expression of SIX2 (b), SIX3 (d), and SIX4 (f) between III–IV and I–II patients in ADC
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The ORs of SIX2 and SIX3 between III–IV and I–II in
GSE68793 (SIX2: OR = 1.62; SIX3: OR = 1.62) showed
consistent trend with pooled OR.
The SIX family gene expressions correlated with LNM of
NSCLC
The correlation between SIX3 expression and LNM of
NSCLC hovered around significance (pooled OR =
1.15, 95 % CI, 0.95–1.39, p = 0.050, and I2 = 57.7 %; see
Additional file 2). The high SIX4 and SIX6 expressions
were linked with the greater possibility of LNM in NSCLC
(SIX4: pooled OR = 3.07, 95 % CI, 1.60–5.92, p = 0.944,
and I2 = 0.0 %; SIX6: pooled OR = 1.22, 95 % CI, 1.00–
1.48, p = 0.429, and I2 = 0.0 %; see Additional file 2). Other
members of the SIX family showed no association with
LNM (see Additional file 2).
The different expressions of the SIX family genes
between lung adenocarcinoma and squamous carcinoma
The relative expressions of SIX2 and SIX4 were found
higher in SQC compared with ADC in NSCLC (SIX2:
pooled OR = 0.63, 95 % CI, 0.57–0.70, p = 0.074, and
I2 = 45.9 %; SIX4: pooled OR = 0.74, 95 % CI, 0.66–
0.82, p = 0.280, and I2 = 19.7 %; Fig. 5a, b).
Impact of the SIX family expression on overall survival for
NSCLC
The prognostic value of the SIX family in NSCLC
was analyzed. SIX2, SIX4, and SIX6 showed signifi-
cant correlation with the poor OS of NSCLC (SIX2:
pooled HR = 1.14, 95 % CI, 1.00–1.31, p = 0.711, and
I2 = 0.0 %; SIX4: pooled HR = 1.39, 95 % CI, 1.16–
1.66, p = 0.749, and I2 = 0.0 %; SIX6: pooled HR = 1.18,
95 % CI, 1.00–1.38, p = 0.242, and I2 = 21.9 %; Fig. 6a,
c, e). However, only SIX4 reached statistically signifi-
cance in poor OS of ADC (pooled HR = 1.48, 95 %
CI, 1.18–1.86, p = 0.420, and I2 = 0.4 %; Fig. 6d). SIX2
and SIX6 approached conventional significance levels
(SIX2: pooled HR = 1.11, 95 % CI, 0.94–1.31, p =
0.552, and I2 = 0.0 %; SIX6: pooled HR = 1.17, 95 %
CI, 0.97–1.41, p = 0.322, and I2 = 13.5 %; Fig. 6b, f ).
However, SIX2, SIX4, and SIX6 had no significance in
improving OS of SQC (see Additional file 3). There
was an obvious relationship between SIX5 expression
and poor OS rate in SQC, while SIX3 showed posi-
tive relation to OS, suggesting a protective effect (see
Additional file 4). The Kaplan-Meier curves indicated
that patients with higher mRNA levels of SIX2, SIX4,
and SIX6 had unfavorable OS time, which represent
poor survival in NSCLC (SIX2: pooled HR = 1.35,
95 % CI, 1.18–1.53, p < 0.001; SIX4: pooled HR = 1.22,
95 % CI, 1.03–1.44, p = 0.022; SIX6: pooled HR = 1.23,
95 % CI, 1.08–1.39, p = 0.0017; Fig. 6g–i).
Effect of the SIX family expression on relapse-free survival
for NSCLC
SIX2 expression was associated with poor RFS in
NSCLC (pooled HR = 1.31, 95 % CI, 1.06–1.63, p =
0.331, and I2 = 13.1 %; Fig. 7a) as well as in ADC (pooled
HR = 1.42, 95 % CI, 1.14–1.77, p = 0.610, and I2 = 0.0 %;
Fig. 7b). SIX4 and SIX6 expressions approached statis-
tical significance on poor RFS in NSCLC (SIX4: pooled
HR = 1.28, 95 % CI, 0.98–1.67, p = 0.363, and I2 = 5.9 %;
SIX6: pooled HR = 1.14, 95 % CI, 0.94–1.39, p = 0.468,
and I2 = 0.0 %; Fig. 7c, e). Nevertheless, subgroup analysis
showed that SIX4 and SIX6 expressions also played a crit-
ical role in poor RFS of ADC (SIX4: pooled HR = 1.52,
95 % CI, 1.09–2.11, p = 0.788, and I2 = 0.0 %; SIX6: pooled
HR = 1.25, 95 % CI, 1.01–1.56, p = 0.908, and I2 = 0.0 %;
Fig. 7d, f ). SIX3 had a positive effect on RFS of SQC (see
Additional file 4), but other SIX members did not reach a
statistical significance (see Additional files 4 and 5). The
Kaplan-Meier curves showed that SIX2 and SIX6 expres-
sions predicted poor RFS of patients diagnosed as NSCLC
(SIX2: pooled HR = 1.83, 95 % CI, 1.51–2.22, p < 0.001;
SIX6: pooled HR = 1.88, 95 % CI, 1.55–2.29, p < 0.001;
Fig. 7g, i), while SIX4 had no significant effect (pooled
HR = 1.05, 95 % CI, 0.8–1.37, p = 0.74; Fig. 7h).
Publication bias
Begg’s test and Egger’s test were employed to get publi-
cation bias statistics. And it did not indicate significant
a b
Fig. 5 Forest plot of odds ratio (OR). CI confidence interval. Relative expression of SIX2 (a) and SIX4 (b) in ADC compared to SQC
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publication bias for the following parameters. SIX1
mRNA expression: NSCLC/normal: Begg’s test p = 0.707,
Egger’s test p = 0.901; ADC/normal: Begg’s test p = 0.806,
Egger’s test p = 0.604. SIX2 mRNA expression: NSCLC/
normal: Begg’s test p = 1.000, Egger’s test p = 0.808;
ADC/normal: Begg’s test p = 0.806, Egger’s test p = 0.577;
III~IV/I~II: Begg’s test p = 0.386, Egger’s test p = 0.324;
ADC-III~IV/ADC-I~II: Begg’s test p = 0.806, Egger’s test
p = 0.405; OS of NSCLC: Begg’s test p = 0.371, Egger’s
test p = 0.238; OS of ADC: Begg’s test p = 0.466, Egger’s
test p = 0.415; RFS of NSCLC: Begg’s test p = 0.806,
Egger’s test p = 0.980; RFS of ADC: Begg’s test p = 0.806,
Egger’s test p = 0.996. SIX3 mRNA expression: NSCLC/






Fig. 6 Forest map of hazard ratio (HR) and Kaplan-Meier survival curve. CI confidence interval. Association between SIX2 (a), SIX4 (c), and SIX6 (e)
with OS of NSCLC. Association between SIX2 (b), SIX4 (d), and SIX6 (f) with OS of ADC. Kaplan-Meier survival curves of SIX2 (g), SIX4 (h), and SIX6
(i) with OS of NSCLS
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ADC/normal: Begg’s test p = 0.806, Egger’s test p = 0.904;
III~IV/I~II: Begg’s test p = 0.536, Egger’s test p = 0.255;
ADC-III~IV/ADC-I~II: Begg’s test p = 0.806, Egger’s test
p = 0.479. SIX4 mRNA expression: NSCLC/normal:
Begg’s test p = 0.734, Egger’s test p = 0.656; ADC/normal:
Begg’s test p = 1.000, Egger’s test p = 0.702; III~IV/I~II:
Begg’s test p = 0.086, Egger’s test p = 0.070; ADC-III~IV/
ADC-I~II: Begg’s test p = 0.308, Egger’s test p = 0.165;
ADC/SQC: Begg’s test p = 0.548, Egger’s test p = 0.871;
OS of NSCLC: Begg’s test p = 0.230, Egger’s test p =
0.062; RFS of NSCLC: Begg’s test p = 0.734, Egger’s test
p = 0.871; RFS of ADC: Begg’s test p = 0.734, Egger’s test
p = 0.381. SIX5 mRNA expression: NSCLC/normal:
Begg’s test p = 1.000, Egger’s test p = 0.638; ADC/normal:
Begg’s test p = 0.086, Egger’s test p = 0.149. SIX6 mRNA






Fig. 7 Forest map of hazard ratio (HR) and Kaplan-Meier survival curve. CI confidence interval. Association between SIX2 (a), SIX4 (c), and SIX6 (e)
with RFS of NSCLC. Association between SIX2 (b), SIX4 (d), and SIX6 (f) with RFS of ADC. Kaplan-Meier survival curves of SIX2 (g), SIX4 (h), and
SIX6 (i) with RFS of NSCLS
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p = 0.196; RFS of NSCLC: Begg’s test p = 0.806, Egger’s
test p = 0.261; RFS of ADC: Begg’s test p = 0.462, Egger’s
test p = 0.377.
Discussion
Molecular classification and targeted therapy improve
outcomes of NSCLC. For example, novel agents target-
ing epidermal growth factor receptor (EGFR) mutation
and echinoderm microtubule-associated protein-like an-
aplastic lymphoma kinase (EML4-ALK) fusion benefit
the patients with advanced ADC [22, 23]. Other molecu-
lar alterations, such as Notch signaling, NLK, and NRF2,
also contribute to NSCLC progression [24–26]. Accord-
ingly, exploring new molecular markers is conducive to
precision treatment. RDGN is a crucial signal of organ
development, especially in lung tissue [1–5]. Aberrant
expression of RDGN confers to tumorigenesis [27, 28].
SIX and EYA were considered as components of RDGN,
which coordinationally regulated cell proliferation, apop-
tosis, tumor growth, and metastasis [27, 28]. Recent
genetic study indicated that another RDGN member
DACH1 is a promising tumor suppressor [29] and
mechanism analysis demonstrated that DACH1 inhibited
cancer proliferation and invasion [30–32]. Consequently,
the detection of this pathway might be used to monitor
tumor progression and predict prognosis of cancer
patients.
It has been acknowledged that the SIX family corre-
lated with progression and prognosis of a diverse range
of tumors [27, 28, 33]. Among them, the SIX1 has been
extensively studied [34]. It has been reported that SIX1
showed great influence on cell proliferation, survival,
and motility by transcriptional regulating cyclin D1 and
c-myc in rhabdomyosarcoma [35] and cyclin A1 in
breast cancer in vitro [36]. Thus, inappropriate expres-
sion of SIX1 can both induce tumorigenesis and pro-
mote metastasis [37]. Nevertheless, the role of SIX1 in
NSCLC has not been eastablished. In this study, we
found that mRNA level of SIX1 was higher in whole
NSCLC tissues compared with normal tissues as well as
in ADC, indicating that SIX1 might be involved in the
tumorigenesis of NSCLC. Xia Y et al. reported that the
expression of SIX1 was associated with heavy tumor
burden, including large tumor size, advanced tumor
stage, and distant metastasis of NSCLC [15]. In in vitro
study, they demonstrated that silencing of endogenous
SIX1 attenuated proliferation and invasion of lung can-
cer, which supported our clinical analysis [15]. But the
role of SIX1 in relation to other clinicopathological pa-
rameters, such as TNM stage and LNM, was ambiguous
in our analysis. We also found that there was no definite
predictive value of SIX1 for the prognosis of NSCLC.
However, Mimae T et al. reported that in microdesected
tissue, mRNA and protein expressions of SIX1 were
elevated in minimally invasive ADC and double upregu-
lation of Notch2 and SIX1 contributed to preinvasive-
to-invasive transition in ADC, suggesting that SIX1
contributed to the progression of ADC [16]. Possible
explanation is that no-tumor cell contamination in no-
microdesected tumor tissue may attenuate the real ex-
pression level of SIX1 in cancer. In addition, increased
SIX1 protein abundance might derive from enhanced
translational regulation and protein stability through
modification. Anyway, functional activation of SIX1
may promote tumor progression.
Our study also demonstrated that the mRNA level of
SIX2 was higher in NSCLC tissues than in normal tis-
sues, suggesting that SIX2 might participate in the
tumorigenesis of NSCLC. Furthermore, we found that
high SIX2 expression was positively correlated with the
high stage which exhibits a greater possibility of inva-
siveness and poor prognosis in NSCLC. The OS and
RFS time were shorter in NSCLC patients with higher
expression of SIX2, whereas subgroup analysis did not
reach significance in ADC and SQC. The mouse model
study has proposed that Six2 promoted breast cancer
metastasis by reducing the E-cadherin [38]. This may ex-
plain the unfavorable prognosis associated with SIX2 in
NSCLC.
SIX3, unlike other members of the SIX family, is a
suppressor in proliferation and migration of lung cancer
cells. Min-Li Mo et al. demonstrated for the first time
that SIX3 over-expression repressed a number of onco-
genic genes related to proliferation and metastasis during
lung carcinogenesis [18]. Furthermore, SIX3 expression
was identified to be associated with improved RFS and OS
in the early stage of ADC patients [18]. Considering SIX3
is the only SIX family member that does not interact with
EYA [11, 13], which is an oncogene, it is reasonable to
comprehend the tumor suppression features of SIX3. Al-
though there was no-statistic significance between SIX3
expression and the OS as well as RFS of NSCLC patients
at the mRNA level in our analysis, subgroup analysis still
suggested that SIX3 could become a prognostic marker
for SQC. Paradoxically, we found that the high expression
of SIX3 was detected in tumor tissues and it was related
to the advanced stage in NSCLC or ADC but not in SQC.
Based on our result and previous publication, we pro-
posed that SIX3 might promote the initiation of NSCLC,
but inhibit tumor progression once tumor formed, espe-
cially in the early stage of lung squamous cell carcinoma.
Another intriguing finding of our analysis is the ex-
pression of SIX4 in NSCLC, which has been rarely stud-
ied. The SIX4 expression was higher in NSCLC or ADC
than in normal tissues. Detailed analysis suggested a
higher expression of SIX4 in SQC than ADC. Significant
correlation between SIX4 expression and high TNM
stage of NSCLC or ADC was found at mRNA level. But
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insufficient researches among our inclusive literatures
referred to the association between SIX4 expression and
TNM stage of SQC. Higher expression of SIX4 con-
ferred to the greater possibility of LNM. Moreover, pa-
tients with higher SIX4 expression showed significantly
poor OS and RFS in NSCLC or ADC. As mentioned
above, SIX4 has the potential to be a novel biomarker in
screening out high risk patients and assessing prognosis
of NSCLC.
SIX5 was supposed as an epithelial differentiation
marker in ovary tissue [39]. There was no published re-
search about the correlation between SIX5 and NSCLC.
Our meta-analysis indicated that the SIX5 was involved
in tumor formation of NSCLC. Apparently, higher ex-
pression of SIX5 was associated with poor OS in SQC.
Therefore, SIX5 may predict the prognosis of SQC.
High frequency methylation of SIX6 promoter was de-
tected in early stage of NSCLC [17]. Although those
methylations were associated with clinical characteristics
of NSCLC, the biological functions were not addressed.
Our analysis revealed that SIX6 was associated with a
greater possibility of LNM in NSCLC. Consistently,
SIX6 were linked to the poor OS in NSCLC and poor
RFS in ADC. Based on the hypothesis that SIX6 regu-
lated proliferation by directly repressing anti-oncogene
p27Kip1 during mammalian retinogenesis and pituitary
development [40], we inferred that inappropriate activa-
tion of SIX6 may promote proliferation of NSCLC by
promoting cell cycle progress.
Heterogeneity tests are indispensable for a meta-
analysis. In this analysis, minor heterogeneities were ob-
served. There are several reasons for the heterogeneities,
including (1) whole genomic expression profiles provide
unbiased quantitative measure of mRNA expression;
however, different platforms of gene expression array
might produce the heterogeneity. (2) Confounding fac-
tors such as race and histology also augment heteroge-
neities in our analysis. (3) Multicenter prospective
studies based on large sample size are required.
Publication bias analysis of clinicopathological param-
eter and survival showed no big variation. In addition,
the following limitations should be considered in our
analysis: (1) we cannot eliminate the potential publica-
tion bias; (2) the inclusive literatures were limited; (3)
the methods for detecting SIX gene expression and cut-
off values were different; and (4) raw data of some re-
searches were not available when conducting this meta-
analysis.
Conclusions
In conclusion, the meta-analysis revealed that the SIX
family might play a pivotal role in the initiation and pro-
gression of NSCLC, especially in ADC. Each member of
SIX family has its own characteristic in tumorigenesis of
NSCLC. SIX1, SIX2, SIX3, SIX4, and SIX5 were detected
at high expression levels in NSCLC tissues. SIX2, SIX3,
and SIX4 were linked to high TNM stages. Higher ex-
pressions of SIX4 and SIX6 correlated with the greater
possibility of LNM. Moreover, the expressions of SIX2,
SIX4, and SIX6 in NSCLC or in ADC indicated poor OS
and RFS. SIX3 and SIX5 were related to OS and RFS of
SQC. Overall, the measurement of the SIX family pro-
vides potential approaches to molecular diagnosis, evalu-
ation of prognosis, and targeted therapy of NSCLC in
the future.
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